Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis
Clinical Summary
View sourceWhat was studied
A retrospective multicenter series evaluated 14 patients with CD30‑positive cutaneous T‑cell lymphoma treated with brentuximab vedotin (BV) plus radiotherapy started within 3 months before/after BV or given simultaneously; low‑dose RTx was common (≤12 Gy in 57%). Median follow‑up was 14.4 months.
Key findings
Adverse events occurred in 71% (10/14), with grade ≥3 in 21% (3/14); common events were peripheral neuropathy, neutropenia, and radiodermatitis. Best overall response was CR 14% (2/14) and PR 79% (11/14); at last assessment CR 14%, PR 29%, SD 7%, PD 50%; median PFS was 12.0 months (95% CI 7.3–NA) with 1‑year PFS 34.0% (95% CI 12.9–90.1).
Study limitations
Very small sample (n=14) with heterogeneous RTx modalities, doses, and BV adjustments; retrospective, single‑arm design without a control group; predominantly advanced‑stage disease and unsystematic documentation limit generalizability.
Clinical implications
Combining BV with RTx (sequentially or concurrently) was feasible and generally well tolerated, with expected toxicities and no new safety signals. Use caution with higher RTx doses and close sequencing, as severe hematologic events were observed with 30 Gy schedules and near‑term BV.
Related Questions
Explore related topics and deepen your understanding